Development and validation of HPLC/UV-procedures of efavirenz determination in biological fluids

Authors

  • O. I. Slabiak Ivano-Frankivsk National Medical University, Ukraine
  • I. M. Ivanchuk Ivano-Frankivsk National Medical University, Ukraine
  • L. Yu. Klimenko National University of Pharmacy, Ukraine
  • Iu. S. Kolisnyk National University of Pharmacy, Ukraine

DOI:

https://doi.org/10.24959/ophcj.19.964

Keywords:

efavirenz, high-performance liquid chromatography, blood, urine, sample preparation, validation

Abstract

Efavirenz is a non-nucleoside reverse transcriptase inhibitor with a number of side effects manifested by psychiatric symptoms. There are cases of acute poisoning due to administration of efavirenz, including cases of suicide attempts; therefore, efavirenz may be approved as a toxic compound in forensic toxicology.

Aim. To apply the MiLiChrome® A-02 HPLC-analyzer system for efavirenz quantitative determination in biological fluids and perform validation of the procedures developed.

Results and discussion. Three HPLC/UV-procedures of efavirenz determination in blood and urine have been proposed. Validation of all procedures developed has been performed by such parameters as specificity, recovery, linearity, accuracy and precision in the variants of the methods of calibration curve and standard. The results of analysis have shown the absence of peaks with the retention time, which is coincident with the efavirenz retention time, on the chromatograms of blank-samples for all variants of procedures of the analyte isolation. All procedures of sample preparation show the high efficiency of efavirenz isolation both for blood and urine (at the level of 90 %). All procedures studied are characterized by the acceptable parameters of linearity, within-run and between-run accuracy and precision.

Experimental part. Sample preparation of blood and urine was carried out in three ways – 1) liquid-liquid extraction with the mixture of chloroform and 2-propanol (80 : 20); 2) 2-propanol extraction and salting-out with ammonium sulfate; 3) acetonitrile extraction and salting-out with ammonium sulfate. The chromatographic conditions were as follows: the column – Ø2 × 75 mm, ProntoSIL 120-5-C18 AQ, 5 μm; temperature – 40 °С; the flow rate – 100 μl/min; Eluent A – 0.2 M LiClO4 – 0.005 M HClO4; Eluent B – acetonitrile; the elution mode – linear gradient; detection – UV, 247 nm; the volume of injection – 2 μl.

Conclusions. The set of HPLC-procedures of efavirenz quantitative determination in blood and urine has been developed. Validation of the procedures developed has been performed.

Downloads

Download data is not yet available.

References

  1. Bastos, M. M., Costa, C. C. P., Bezerra, T. C., da Silva, F. C., Boechat, N. (2016). Efavirenz a nonnucleoside reverse transcriptase inhibitor of first-generation: approaches based on its medicinal chemistry. European Journal of Medicinal Chemistry, 108, 455–465. https://doi.org/10.1016/j.ejmech.2015.11.025
  2. Waters, L., John, L., Nelson, M. (2007). Non-nucleoside reverse transcriptase inhibitors: a review. International Journal of Clinical Practice, 61 (1), 105–118. https://doi.org/10.1111/j.1742-1241.2006.01146.x
  3. Porche, D. J. (2000). Efavirenz. Journal of the Association of Nurses in Aids Care, 11 (3), 95–98. https://doi.org/10.1016/s1055-3290(06)60280-x
  4. Andany, N., Gold, W. L. (2016). Single–tablet antiretroviral treatment (once daily). Canadian Medical Association Journal, 188 (13), 971. https://doi.org/10.1503/cmaj.151412
  5. Kenedi, C. A., Goforth, H. W. (2011). A systematic review of the psychiatric side-effects of efavirenz. AIDS and Behavior, 15 (8), 1803–1818. https://doi.org/10.1007/s10461-011-9939-5
  6. Decloedt, E. H., Maartens, G. (2013). Neuronal toxicity of efavirenz: a systematic review. Expert Opinion on Drug Safety, 12 (6), 841–846. https://doi.org/10.1517/14740338.2013.823396
  7. Abers, M. S., Shandera, W. X., Kass, J. S. (2014). Neurological and psychiatric adverse effects of antiretroviral drugs. CNS Drugs, 28 (2), 131–145. https://doi.org/10.1007/s40263-013-0132-4
  8. Mutwa, P. R., Fillekes, Q., Malgaz, M., Tuyishimire, D., Kraats, R., Boer, K. R., Burger, D. M., van Schaik, R. H., Muganga, N., Geelen, S. P. (2012). Mid-dosing interval efavirenz plasma concentrations in HIV–1–infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. Journal of Acquired Immune Deficiency Syndromes, 60 (4), 400–404. https://doi.org/10.1097/qai.0b013e3182569f57
  9. Fillekes, Q., Natukunda, E., Balungi, J., Kendall, L., Bwakura-Dangarembizi, M., Keishanyu, R., Ferrier, A., Lutakome, J., Gibb, D. M., Burger, D. M., Walker, A. S. (2011). Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. Journal of Acquired Immune Deficiency Syndromes, 58 (4), 392–398. https://doi.org/10.1097/qai.0b013e318235e560
  10. Mollan, K. R., Smurzynski, M., Eron, J. J., Daar, E. S., Campbell, T. B., Sax, P. E., Gulick, R. M., Na, L., O’Keefe, L., Robertson, K. R., Tierney, C. (2014). Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data. Annals of Internal Medicine, 161 (1), 1–10. https://doi.org/10.7326/m14-0293
  11. Efavirenz: suicides. (2015). Prescrire International, 24 (161), 156.
  12. Curley, P., Siccardi, M., Moss, D. M., Owen, A. (2016). Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. Bioanalysis, 8 (20), 2125–2134. https://doi.org/10.4155/bio-2016-0021
  13. Montgomery, E. R., Edmanson, A. L., Cook, S. C., Hovsepian, P. K. (2001). Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation. Journal of Pharmaceutical and Biomedical Analysis, 25 (2), 267–284. https://doi.org/10.1016/s0731-7085(00)00495-7
  14. Saras-Nacenta, M., López-Púa, Y., Lípez-Cortés, L. F., Mallolas, J., Gatell, J. M., Carné, X. (2001). Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. Journal of Chromatography B: Biomedical Sciences and Applications, 763 (1–2), 53–59. https://doi.org/10.1016/s0378-4347(01)00357-7
  15. Ramachandran, G., Kumar, A. K., Swaminathan, S., Venkatesan, P., Kumaraswami, V., Greenblatt, D. J. (2006). Simple and rapid liquid chromatography method for determination of efavirenz in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 835 (1–2), 131–135. https://doi.org/10.1016/j.jchromb.2006.03.014
  16. Barreiros, L., Cunha-Reis, C., Silva, E. M., Carvalho, J. R., das Neves, J., Sarmento, B., Segundo, M. A. (2017). Development and validation of a liquid chromatography-MS/MS method for simultaneous quantification of tenofovir and efavirenz in biological tissues and fluids. Journal of Pharmaceutical and Biomedical Analysis, 136, 120–125. https://doi.org/10.1016/j.jpba.2016.12.028
  17. Azarova, I. N., Baram, G. I. (2014). Sorbtsionnye i Khromatograficheskie Protsessy, 14 (1), 858–867.
  18. Slabiak, O. I., Ivanchuk, I. M., Klimenko, L. Yu., Tokaryk, G. V., Lebedynets, V. O., Yaremenko, V. D. (2018). Development and validation of HPLC/UV-procedure for efavirenz quantitative determination. Journal of Pharmaceutical Sciences and Research, 10 (11), 2829–2835.
  19. Klymenko, L. Yu. (2015). Kompleksnyi pidkhid do rozrobky ta validatsii metodyk kilkisnoho vyznachennia analitiv u biolohichnykh ridynakh v khimiko-toksykolohichnomu analizi. Doctor’s thessis. Kharkiv, 816.
  20. Guidance for the Validation of Analytical Methodology and Calibration of Equipment used for Testing of Illicit Drugs in Seized Materials and Biological Specimens (2009). United Nations Office on Drugs and Crime, Laboratory and Scientific Section,New York.
  21. Slabiak, O. I., Ivanchuk, I.M., Klimenko, L. Yu., Mykytenko, O. Ye. (2018). Study of efavirenz extraction from aqueous solutions. Nauka i innovaciia, 1, 165–171.

Downloads

Published

2019-03-13

How to Cite

(1)
Slabiak, O. I.; Ivanchuk, I. M.; Klimenko, L. Y.; Kolisnyk, I. S. Development and Validation of HPLC/UV-Procedures of Efavirenz Determination in Biological Fluids. J. Org. Pharm. Chem. 2019, 17, 48-57.

Issue

Vol. 17 No. 1(65) (2019)

Section

Original Researches

License

Copyright (c) 2019 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).